Health news
Gabapentin detection and involvement in drug overdose deaths were found to have increased from 2019 to 2020, according to a recent Morbidity and Mortality Weekly Report published by the Centers for Disease Control and Prevention…
In an effort to address the ongoing opioid epidemic, the White House has released the 2022 National Drug Control Strategy. The Strategy focuses on 2 main drivers of the opioid epidemic: drug trafficking and untreated…
In an effort to reduce unnecessary exposure to opioids, the Food and Drug Administration (FDA) is considering a mail-back envelope requirement that would provide an additional disposal option for individuals who receive opioid analgesics in…
The Food and Drug Administration (FDA) has approved Naloxone Auto-Injector 10mg (naloxone hydrochloride injection) for use by military personnel and chemical incident responders for the emergency treatment of individuals 12 years of age and older…
In an effort to further combat the opioid crisis, the Food and Drug Administration (FDA) has issued draft guidance addressing the development of novel analgesic drugs that have the potential to decrease opioid use and…
On October 13 and 14, 2021, the United States Food and Drug Administration (FDA) held a 2-day virtual public workshop to discuss mandatory opioid prescriber education as part of the Risk Evaluation and Mitigation Strategy…
The Food and Drug Administration (FDA) has granted Fast Track designation to OPNT003 (nasal nalmefene) for the treatment of opioid overdose. OPNT003 is being developed as an alternative to naloxone to reverse the effects of…
The Food and Drug Administration (FDA) has approved Seglentis® (celecoxib and tramadol hydrochloride) for the management of acute pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments…
The Food and Drug Administration (FDA) has approved Zimhi (naloxone hydrochloride) injection for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. Zimhi is an opioid…
The Food and Drug Administration (FDA) will be holding a 2-day virtual public workshop to reconsider the need for mandatory opioid prescriber education as part of the Risk Evaluation and Mitigation Strategy (REMS). In 2012,…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021